CliffBio
small molecule

MYFEMBREE

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Loss of exclusivityNovember 2042latest FDA-listed patent expiry
CompanySumitomo Pharma America →See this company's full patent-cliff portfolio

Drug detail

Brand nameMYFEMBREE
Active ingredientESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Strength1MG;0.5MG;40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2021
Marketing statusRX

Listed patents

PatentExpiresType
12551447November 2042product
11793812May 2038use U-2360
11957684September 2037use U-3129
11033551September 2037use U-3129
11795178September 2033substance, product
12325714September 2033substance, product
7300935January 2029substance
8058280January 2026substance, product

Regulatory exclusivity

CodeExpires
M-289January 2026

More from Sumitomo Pharma America

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.